Meiyu Fang

Nov 1, 2024 | jitc.bmj.com | Bin Lian |Yu Chen |Meiyu Fang |Cuihua Yi

Late-Breaking AbstractsClinical Trial In Progress 1502 Efficacy and safety results of first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein IBI363 in patients with immunotherapy-naïve advanced melanoma Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service.

Oct 1, 2024 | jitc.bmj.com | Bixia Tang |Yu Chen |Yu Jiang |Meiyu Fang

MethodsThis multicenter, open-label, phase I clinical trial consisted of two parts—dose-escalation phase (part 1) and dose-expansion phase (part 2). Patients were enrolled from nine centers in China. Eligible participants were 18 years or older with histopathologically confirmed advanced or recurrent solid tumors per American Joint Committee on Cancer eighth edition (melanoma of uveal origin was not included).

Apr 21, 2023 | mdpi.com | Zhe Zhu |Meiyu Fang

Open AccessArticlebyMeiyu Fang 1,*,† and Zhe Zhu 2,† 1School of International Business, Zhejiang International Studies University, Hangzhou 310023, China2School of Economics, Zhejiang University of Technology, Hangzhou 310023, China*Author to whom correspondence should be addressed. †These authors contributed equally to this work.